자유게시판

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications don't work for a majority of patients suffering from depression. The individual approach to treatment could be the answer.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into personalised micro-interventions to improve mental health. We analyzed the best-fitting personalized ML models to each subject, using Shapley values to discover their feature predictors. The results revealed distinct characteristics that were deterministically changing mood over time.

Predictors of Mood

Depression is a major cause of mental illness in the world.1 Yet only half of those with the condition receive treatment. To improve the outcomes, clinicians need to be able to identify and treat patients who have the highest likelihood of responding to particular treatments.

The ability to tailor depression treatments is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from specific treatments. They use sensors on mobile phones and a voice assistant incorporating artificial intelligence, and other digital tools. Two grants worth more than $10 million will be used to identify biological and behavioral predictors of response.

To date, the majority of research on factors that predict depression treatment effectiveness has been focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, sex and education, clinical characteristics including symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

Few studies have used longitudinal data to determine mood among individuals. A few studies also consider the fact that mood can be very different between individuals. Therefore, it is crucial to develop methods which allow for the analysis and measurement of individual differences in mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to develop algorithms that can detect various patterns of behavior and emotion that are different between people.

The team also developed a machine-learning algorithm that can identify dynamic predictors of each person's depression mood. The algorithm combines the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype has been correlated with CAT DI scores that are a psychometrically validated symptoms severity scale. However, the correlation was weak (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1, but it is often not properly diagnosed and treated. In addition, a lack of effective interventions and stigma associated with depression disorders hinder many individuals from seeking help.

To allow for individualized treatment to improve treatment, identifying the patterns that can predict symptoms is essential. However, the methods used to predict symptoms are based on the clinical interview, which has poor reliability and only detects a limited number of features that are associated with depression.2

Machine learning can be used to blend continuous digital behavioral phenotypes captured by sensors on smartphones and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of severity of symptoms could improve diagnostic accuracy and increase treatment efficacy for depression. Digital phenotypes are able to are able to capture a variety of distinct behaviors and activities that are difficult to capture through interviews and permit high-resolution, continuous measurements.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were directed to online support or clinical care based on the severity of their depression treatment history. Those with a CAT-DI score of 35 or 65 were given online support with a coach and those with scores of 75 patients were referred to in-person clinical care for psychotherapy.

At the beginning of the interview, participants were asked an array of questions regarding their personal demographics and psychosocial characteristics. The questions asked included education, age, sex and gender and financial status, marital status and whether they were divorced or not, their current suicidal thoughts, intent or attempts, as well as the frequency with which they consumed alcohol. The CAT-DI was used to rate the severity of depression-related symptoms on a scale ranging from 100 to. CAT-DI assessments were conducted every week for those that received online support, and every week for those who received in-person support.

Predictors of Treatment Response

Research is focusing on personalized treatment for depression. Many studies are aimed at finding predictors that can help clinicians identify the most effective drugs for each person. In particular, pharmacogenetics identifies genetic variations that affect how the body metabolizes antidepressants. This allows doctors to select the medications that are most likely to work best for each patient, while minimizing the time and effort in trial-and-error treatments and eliminating any side effects that could otherwise hinder advancement.

Another promising approach is to create predictive models that incorporate the clinical data with neural imaging data. These models can be used to determine the most effective combination of variables that is predictors of a specific outcome, like whether or not a particular medication will improve mood and symptoms. These models can be used to determine the patient's response to an existing treatment which allows doctors to maximize the effectiveness of their treatment currently being administered.

A new type of research utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to combine the effects of multiple variables and increase predictive accuracy. These models have been demonstrated to be effective in predicting treatment outcomes like the response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the standard for the future of clinical practice.

In addition to ML-based prediction models research into the mechanisms behind depression is continuing. Recent research suggests that the disorder is connected with neurodegeneration in particular circuits. This suggests that an individualized hormonal depression treatment treatment will be built around targeted therapies that target these neural circuits to restore normal functioning.

Internet-delivered interventions can be a way to accomplish this. They can offer an individualized and tailored experience for patients. For instance, one study found that a web-based program was more effective than standard treatment in reducing symptoms and ensuring a better quality of life for those with MDD. Furthermore, a randomized controlled study of a personalised approach to treating depression showed sustained improvement and reduced adverse effects in a significant percentage of participants.

Predictors of side effects

A major issue in personalizing depression treatment involves identifying and predicting which antidepressant medications will have very little or no side effects. Many patients are prescribed a variety medications before finding a medication that is both effective and well-tolerated. Pharmacogenetics offers a new and exciting method of selecting antidepressant medicines that are more effective and specific.

There are many predictors that can be used to determine the antidepressant that should be prescribed, including gene variations, phenotypes of the patient such as gender or ethnicity and comorbidities. However, identifying the most reliable and accurate factors that can predict the effectiveness of a particular treatment is likely to require randomized controlled trials with significantly larger numbers of participants than those typically enrolled in clinical trials. This is because it could be more difficult to identify moderators or interactions in trials that only include one episode per participant rather than multiple episodes over a long period of time.

Furthermore to that, predicting a patient's reaction will likely require information about comorbidities, symptom profiles and the patient's personal perception of the effectiveness and tolerability. Presently, only a handful of easily identifiable sociodemographic and clinical variables are believed to be reliable in predicting the response to MDD, such as gender, age, race/ethnicity and SES BMI, the presence of alexithymia, and the severity of depression symptoms.

The application of pharmacogenetics in depression treatment is still in its beginning stages and there are many hurdles to overcome. First, it is essential to have a clear understanding and definition of the genetic mechanisms that underlie depression, as well as an understanding of a reliable predictor of treatment response. Ethics like privacy, and the ethical use of genetic information are also important to consider. In the long-term, pharmacogenetics may provide an opportunity to reduce the stigma associated with Mental Depression Treatment (Historydb.Date) health treatment and improve non medical treatment for depression outcomes for those struggling with depression. As with any psychiatric approach, it is important to take your time and carefully implement the plan. At present, it's recommended to provide patients with a variety of medications for depression that are effective and encourage them to speak openly with their physicians.